Articles

Patients with cardiac implantable electronic devices (CIEDs) who received an SGLT2i had a significantly lower incidence of atrial arrhythmia (AA) compared to placebo. 

DAPA-CKD trial results indicate a significant benefit for SGLT2 inhibitor dapagliflozin in reducing chronic kidney disease progression and mortality caused by kidney failure and cardiovascular disease, regardless of diabetes status. 

A new report shows the growing rise in diabetes and prediabetes, but what can be done about it? An interview with the president of ADCES shines a light on this emergent issue and offers ways to help reduce this growth by spreading education. 

Results from using GlucosePATH in Medicaid patients reveal the benefits of clinical decision support software in reducing HbA1c, reducing the risk of disease complications, and improving access to care. 

Hyperuricemia has been implicated in the development and progression of chronic kidney disease, and the effects of intensive albuminuria lowering may be beneficial. 

According to the American Diabetes Association (ADA) Professional Practice Committee, these are the updated changes to standards of medical care in diabetes.

Trials tested the hypothesis that treating patients with intensive therapy to target normal glycated hemoglobin A1c levels would positively affect cardiovascular risk. 

According to research presented by Dr. Anne Cathrine Thorup at the Aarhus University Hospital in Denmark, proper vegetable selection can reduce BMI, total body fat mass, HbA1c levels, and fasting glucose levels. 

Study found sepsis was independently associated with a fourfold increased risk of death in patients with type 2 diabetes. 

Baseline hemoglobin A1C may be inversely proportional to the risk of statin-induced new-onset diabetes.